In recent years, increasing studies suggested that FEZF1-AS1 was significantly overexpressed in many types of human cancers, such as lung cancer [18–21], breast cancer [22], liver cancer [23,24], gastric cancer [25–27], colorectal cancer [28,29], pancreatic cancer [30,31], ovarian cancer [32], cervical cancer [33], osteosarcoma [34], nasopharyngeal carcinoma [35] and multiple myeloma [36]. This evidence concerns the gene FEZF1 and plasma cell myeloma.